Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lyndon M Gommersall

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Nature Clinical Practice. Oncology|November 3, 2005
Current challenges in Wilms' tumor managementLyndon M Gommersall, Manit Arya, Imran Mushtaq, et al.
BJU International|August 18, 2005
Non-myeloablative allogeneic stem cell transplantation: a promising new therapy in the management of metastatic renal cell cancerManit Arya, Lyndon M Gommersall, Iqbal S Shergill, et al.
Expert Opinion on Pharmacotherapy|December 11, 2002
Luteinising hormone releasing hormone analogues in the treatment of prostate cancerLyndon M Gommersall, Dickon Hayne, Iqbal S Shergill, et al.
The Journal of Steroid Biochemistry and Molecular Biology|July 1, 2004
Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cellsLyndon M Gommersall, Farhat L Khanim, Donna M Peehl, et al.
Journal of Medicinal Food|September 24, 2004
Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cellsMartin Albrecht, Wenguo Jiang, James Kumi-Diaka, et al.
Biomarkers in Cancer|January 19, 2018
HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder CancerMark O Kitchen, Richard T Bryan, Richard D Emes, et al.
Oncogene|August 10, 2004
Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cellsFarhat L Khanim, Lyndon M Gommersall, Victoria H J Wood, et al.
Carcinogenesis|May 15, 2010
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesionSebastiano Battaglia, Orla Maguire, James L Thorne, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Nature Clinical Practice. Oncology|November 3, 2005
Current challenges in Wilms' tumor managementLyndon M Gommersall, Manit Arya, Imran Mushtaq, et al.
BJU International|August 18, 2005
Non-myeloablative allogeneic stem cell transplantation: a promising new therapy in the management of metastatic renal cell cancerManit Arya, Lyndon M Gommersall, Iqbal S Shergill, et al.
Expert Opinion on Pharmacotherapy|December 11, 2002
Luteinising hormone releasing hormone analogues in the treatment of prostate cancerLyndon M Gommersall, Dickon Hayne, Iqbal S Shergill, et al.
The Journal of Steroid Biochemistry and Molecular Biology|July 1, 2004
Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cellsLyndon M Gommersall, Farhat L Khanim, Donna M Peehl, et al.
Journal of Medicinal Food|September 24, 2004
Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cellsMartin Albrecht, Wenguo Jiang, James Kumi-Diaka, et al.
Biomarkers in Cancer|January 19, 2018
HumanMethylation450K Array-Identified Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-muscle Invasive Bladder CancerMark O Kitchen, Richard T Bryan, Richard D Emes, et al.
Oncogene|August 10, 2004
Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cellsFarhat L Khanim, Lyndon M Gommersall, Victoria H J Wood, et al.
Carcinogenesis|May 15, 2010
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesionSebastiano Battaglia, Orla Maguire, James L Thorne, et al.
Pageof 1